BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Announces $50 Million Private Placement

MannKind (MNKD)MannKindFinancing

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced

Related news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SGMTSagimet Biosciences2026-09-30 10:19 EST

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

VKTXViking Therapeutics2026-09-24 11:05 EST

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

SGMTSagimet Biosciences2026-10-01 20:31 EST

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States